Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Hepatitis B Vaccinated Children Not At Increased Risk Of MS
The majority of children vaccinated against hepatitis B are not at an increased risk of developing multiple sclerosis (MS). The study based in France involved 349 children with MS and 2,941 children without the disease. The children were all under the

Drug Watch: Agents in late-stage development for the treatment of hepatitis B and C virus infections (October 2008) (PDF)
Extract not available.

Biolex Therapeutics Completes $60 Million Series D Financing To Accelerate Development Of Locteron In Hepatitis C
Extract not available.

UPDATES AND COMMENTARY RSS Feed

Medical Device Boasts Encouraging Data for Hepatitis C Treatment
A medical device designed to clear viruses and immunosuppressive proteins from the blood reduced Hepatitis C viral load for several people on dialysis. Further case studies will determine if the Aethlon Hemopurifier® can induce a rapid virological response against Hepatitis...

Hepatitis C Study Increases Interest in SCV-07
Trial results show SciClone's SCV-07 effectively reduces Hepatitis C viral load in previous non-responders with genotype 1. Based on these encouraging results, a follow-up study to evaluate SCV-07's potential to replace or improve the current Hepatitis C standard treatment will...

New Hope for HCV
Funded by Pfizer, Tacere's licensed RNAi technology could change the way Hepatitis C is treated. A mechanism that inhibits genes from transferring information and creating new genetic material, RNAi-based drugs may be able to silence the genes that cause disease....

J Gastroenterol Hepatol 1997 Aug;12(8):582-584

Effect of shunt surgery on spleen size, portal pressure and esophageal varices in patients with non-cirrhotic portal hypertension.

Sharma BC, Singh RP, Chawla YK, Narasimhan KL, Rao KL, Mitra SK, Dilawari JB

Shunt surgery is considered to be the treatment of choice in patients with non-cirrhotic portal hypertension. There is little data on the effect of side-to-side lieno-renal (SSLR) shunt on oesophageal variceal size, splenic size and splenic pulp pressure (SPP) in patents with non-cirrhotic portal hypertension. We evaluated pre- and postoperatively endoscopic grading of varices, splenic size and SPP for predicting shunt patency in 86 patients with non-cirrhotic portal hypertension: 56 with extrahepatic portal venous obstruction (EHPVO) and 30 with non-cirrhotic portal fibrosis (NCPF). The EHPVO patients with patent shunts (n = 47) showed significant reduction in SPP (pre-operative 43.56 +/- 7.9 vs postoperative 29.96 +/- 0.5 vs 0.92 +/- 0.8). Patients with blocked shunt (n = 9) did not show significant reduction in SPP and varices grades. However, there was reduction in spleen size (8.6 +/- 3.0 vs 6.3 +/- 4.3). In the NCPF group, 28 had patent shunts and showed significant reduction in SPP (46.3 +/- 13.5 vs 33.8 +/- 7.6 cm of saline), splenic size (9.1 +/- 3.3 vs 6.8 +/- 4.6 cm below costal margin) and varices grades (2.8 +/- 0.7 vs 1.05 +/- 0.96). As only two patients with NCPF had blocked shunts, no statistical comparison between patients with patent and patients with blocked shunts could be done. In conclusion, following SSLR, there is a significant reduction in SPP and varices grades in patients with patent shunts. Endoscopic grading of varices can be used to predict shunt patency. However, spleen size is not a good criteria for predicting shunt patency.

PMID: 9304510, UI: 97449494

table Of Contents

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 07 Oct 2008